Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000895307 | SCV001039340 | likely benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002501497 | SCV002810639 | likely benign | Epilepsy, childhood absence, susceptibility to, 6; Hyperaldosteronism, familial, type IV | 2022-05-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002540133 | SCV003740049 | uncertain significance | Inborn genetic diseases | 2022-11-21 | criteria provided, single submitter | clinical testing | The c.2269G>C (p.G757R) alteration is located in exon 10 (coding exon 9) of the CACNA1H gene. This alteration results from a G to C substitution at nucleotide position 2269, causing the glycine (G) at amino acid position 757 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |